Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) announced its participation at the 2023 American Academy of Neurology (AAN) Annual Meeting, showcasing its XEN1101 epilepsy program. An oral presentation by Dr. Jacqueline French will detail interim results from the open-label extension of the Phase 2b X-TOLE study, highlighting a sustained monthly seizure frequency reduction of 80%-90% from baseline and seizure freedom in 17.5% and 10.5% of patients for ≥6 and ≥12 months, respectively. Additionally, Xenon will present its Phase 3 study, X-ACKT, which evaluates XEN1101 in primary generalized tonic-clonic seizures, aiming for regulatory submissions. The trial will assess the drug's safety and efficacy in approximately 160 patients.